Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.
Wang Z, Hu H, Heitink L, Rogers K, You Y, Tan T, Suen CLW, Garnham A, Chen H, Lieschke E, Diepstraten ST, Chang C, Chen T, Moujalled D, Sutherland K, Lessene G, Sieber OM, Visvader J, Kelly GL, Strasser A. Wang Z, et al. Among authors: lieschke e. Cell Death Differ. 2023 Apr;30(4):1033-1046. doi: 10.1038/s41418-023-01122-3. Epub 2023 Feb 4. Cell Death Differ. 2023. PMID: 36739334 Free PMC article.
Correction to: The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.
Wang Z, Hu H, Heitink L, Rogers K, You Y, Tan T, Suen CLW, Garnham A, Chen H, Lieschke E, Diepstraten ST, Chang C, Chen T, Moujalled D, Sutherland K, Lessene G, Sieber OM, Visvader J, Kelly GL, Strasser A. Wang Z, et al. Among authors: lieschke e. Cell Death Differ. 2023 Apr;30(4):1096. doi: 10.1038/s41418-023-01137-w. Cell Death Differ. 2023. PMID: 36828917 Free PMC article. No abstract available.
Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells.
Wang Z, Burigotto M, Ghetti S, Vaillant F, Tan T, Capaldo BD, Palmieri M, Hirokawa Y, Tai L, Simpson DS, Chang C, Huang AS, Lieschke E, Diepstraten ST, Kaloni D, Riffkin C, Huang DCS, Li Wai Suen CSN, Garnham AL, Gibbs P, Visvader JE, Sieber OM, Herold MJ, Fava LL, Kelly GL, Strasser A. Wang Z, et al. Among authors: lieschke e. Cancer Discov. 2024 Feb 8;14(2):362-379. doi: 10.1158/2159-8290.CD-23-0402. Cancer Discov. 2024. PMID: 37877779 Free PMC article.
Mouse models to investigate in situ cell fate decisions induced by p53.
Lieschke E, Thomas AF, Kueh A, Atkin-Smith GK, Baldoni PL, La Marca JE, Young S, Huang AS, Ross AM, Whelan L, Kaloni D, Tai L, Smyth GK, Herold MJ, Hawkins ED, Strasser A, Kelly GL. Lieschke E, et al. EMBO J. 2024 Oct;43(19):4406-4436. doi: 10.1038/s44318-024-00189-z. Epub 2024 Aug 19. EMBO J. 2024. PMID: 39160273 Free PMC article.
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Nesic K, Krais JJ, Wang Y, Vandenberg CJ, Patel P, Cai KQ, Kwan T, Lieschke E, Ho GY, Barker HE, Bedo J, Casadei S, Farrell A, Radke M, Shield-Artin K, Penington JS, Geissler F, Kyran E, Betsch R, Xu L, Zhang F, Dobrovic A, Olesen I, Kristeleit R, Oza A, McNeish I, Ratnayake G, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Bowtell DDL, Harding TC, Lin K, Swisher EM, Kondrashova O, Scott CL, Johnson N, Wakefield MJ. Nesic K, et al. Among authors: lieschke e. Mol Cancer. 2024 Aug 5;23(1):158. doi: 10.1186/s12943-024-02048-1. Mol Cancer. 2024. PMID: 39103848 Free PMC article.
20 results